Mannkind Corporation
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Mannkind Corporation sits in the top decile of US sponsors by registered trial count (#420 of 15,742 sponsors by registered trial count).
Mannkind Corporation: 42 sponsored US clinical trials, 3 recruiting.
Mannkind Corporation sponsors 42 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 30 completed. 15 of these trials are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetes Mellitus, Type 1, with 3 trials.
Top-decile sponsor footprint
Mannkind Corporation ranks in the top decile of sponsors by registered trial count (#420 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
30 of 38 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
42 total, page 1 of 1
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
NCT07224321
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis
NCT07344558
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers
NCT06532942
Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
NCT07679893
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
NCT06418711
INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
NCT05904743
Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes
NCT05243628
Afrezza® INHALE-1 Study in Pediatrics
NCT04974528
Afrezza® Dosing Optimization Study
NCT04849845
Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers
NCT03464864
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
NCT02527265
Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers
NCT01982604
Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge
NCT01902121
Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes
NCT01544881
Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler
NCT01490762
Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus
NCT01451398
Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period
NCT01445951
Pharmacokinetic Study in Healthy Volunteers
NCT01365117
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
NCT01026051
Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166
NCT01201928
Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler
NCT01196104
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
NCT00642616
Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake
NCT00747006
A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)
NCT00757367
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.
NCT00688090
Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks
NCT00700622
A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro
NCT00662857
A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.
NCT00721344
Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal Challenge
NCT00642681
Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function
NCT00626249
A 2-Month Safety Follow-Up Trial
NCT00741429
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
NCT00423254
A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)
NCT01021891
Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma
NCT00332826
Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up
NCT00309244
Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes
NCT00308308
Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes
NCT00308737
Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes
NCT00332488
Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 Diabetes
NCT00934414
An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial
NCT00754624
Vaccine Therapy in Treating Patients With Stage IV Melanoma
NCT00033228
Vaccine Therapy in Treating Patients With Stage IV Melanoma
NCT00023647
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 8 |
| Phase 3 | 12 |
| Phase 4 | 3 |
What is open in the Mannkind Corporation pipeline
3 recruiting of 42 indexed (7% open); 30 completed (71%).
Phase mix: 15 late (III/IV) vs 24 early (I/II) (early-phase heavy).
Top condition: Diabetes Mellitus, Type 1 (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Mannkind Corporation: open-pipeline peers nationwide
Peers matched on 42 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
Mannkind Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 42 trials (± recruiting share)
- Academic and Community Cancer Research United · 42 trials · 14% recruiting
- Ascensia Diabetes Care · 42 trials · 0% recruiting
- Avid Radiopharmaceuticals · 42 trials · 0% recruiting
- Celldex Therapeutics · 42 trials · 7% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Carol Fabian, MD · 7% recruiting · 14 trials
- Kaiser Permanente · 7% recruiting · 294 trials
- Minneapolis Veterans Affairs Medical Center · 7% recruiting · 28 trials
- Ocuphire Pharma · 7% recruiting · 14 trials
Related
What to do with this Mannkind Corporation page
42 registered trials is a research-attention snapshot, not an endorsement of Mannkind Corporation or any single study.
- 3 of Mannkind Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Diabetes Mellitus, Type 1 is the condition Mannkind Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetes Mellitus, Type 1 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Mannkind Corporation pipeline card: 42 registered trials from official public datasets.Report a data error.